PEP-010 is under clinical development by PEP-Therapy and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PEP-010’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PEP-010 (DPTC-9h) is under development for the treatment of metastatic solid tumors including triple negative breast cancer, platinum resistant ovarian cancer. The drug candidate is a recombinant peptide (30 amino acids) constituting two sequences, DPT as a penetrating peptide and PEP1 as the interfering active peptide. It acts by targeting protein phosphatase 2A (PP2A). It is developed based on cell penetrating and interfering peptides (CP and IP) technology. It is administered through intravenous route. It was also under development for chronic lymphocytic leukemia (CLL) and lung cancer.
PEP-Therapy is a medical biotechnology company that develops targeted therapies for treatment of cancer. The company develops cell penetrating and interfering peptides for the intracellular delivery of targeted therapies. Its pipeline products include PEP-010. PEP-Therapy’s PEP-010 includes penetrating shuttle to deliver the active peptide into the cell, and an interfering active peptide blocking Caspase-9/PP2A interaction. The company’s product is used for the treatment of triple-negative breast cancer, lung and ovary cancers, and chronic lymphocytic leukemia. It also conducts clinical trials and licenses the novel therapeutic products and companion biomarkers to both pharmaceutical and biotech companies for their development and commercialization. PEP-Therapy is headquartered in Paris, France.
For a complete picture of PEP-010’s drug-specific PTSR and LoA scores, buy the report here.